Startseite
lx arp1

Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma

Von einem Mystery-Man-Autor

Beschreibung
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma
Frontiers Soluble and Cell–Cell-Mediated Drivers of Proteasome
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma
IJMS, Free Full-Text
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma
Aberrant activation of TRIP13-EZH2 signaling axis promotes
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma
Frontiers FBXW7 and the Hallmarks of Cancer: Underlying
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma
Triad3A-Dependent TLR4 Ubiquitination and Degradation Contributes
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma
Aberrant activation of TRIP13-EZH2 signaling axis promotes
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma
Immune activation is essential for the antitumor activity of EZH2
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma
Immune activation is essential for the antitumor activity of EZH2
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma
PRC2 specifies ectoderm lineages and maintains pluripotency in
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma
Frontiers FBXW7 and the Hallmarks of Cancer: Underlying
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma
Addgene: lentiCRISPR v2 Citations
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma
Research articles
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma
Multiple myeloma mesenchymal stromal cells: Contribution to
aus pro Erwachsener (Preis variiert je nach Gruppengröße)